Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical Progression in Patients with Metastatic Hormone-Sensitive Prostate Cancer By Ogkologos - May 27, 2025 278 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a post-hoc analysis of the ENZAMET study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with... July 29, 2025 After A Long And Dangerous Battle, Africa Has Been Declared Free... August 26, 2020 Cancer in My Community: Working to Expand Access to Clinical Trials... September 22, 2022 Alcohol Tied to 750,000 Cancer Cases Worldwide in 2020 August 12, 2021 Load more HOT NEWS Belzutifan Approved to Treat Tumors Linked to Inherited Disorder VHL Spotlight On: Occupational Therapists in Cancer Care How the National Cancer Act Has Made a Difference in Cancer... 5-Year-Old Boy Meets Generous Stem Cell Donor Who Cured Him
